TITLE

Oral Prostacyclins/Analogs for PAH: Current Status and Challenges

AUTHOR(S)
Rubin, Lewis
PUB. DATE
June 2012
SOURCE
Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the current status and challenges of prostacyclin therapy to pulmonary hypertension (PH) patients. It claims that different studies have been conducted whose goal is to explore the effectiveness of three main prostanoids including treprostinil, beraprost and selexipag. It indicates that patients with PH have been treated with prostanoids intravenously and subcutaneously. However, it notes that effective dosing and pharmacokinetics are yet to be further studied in the future.
ACCESSION #
78326094

 

Related Articles

  • Prostacyclins in Pulmonary Hypertension: The Need for Earlier Therapy. Vachiéry, Jean-Luc // Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p8 

    The article examines clinical trials of prostacyclins in patients with pulmonary arterial hypertension (PAH). It mentions a diagnostic algorithm from the European Society of Cardiology and the European Respiratory Society which suggests the effectiveness of prostacyclin therapies for PAH...

  • BROMELAIN: AN ANTI-INFLAMMATORY AGENT. Seligman, Bert // Angiology;Nov1962, Vol. 13 Issue 11, p508 

    Discusses the pharmacological characteristics of bromelain. Functions of bromelain; Arterial diseases that can be manage with bromelain; Indications of bromelain.

  • ‘Hedged’ Prescribing for Partially Compliant Patients. Urquhart, John; Vrijens, Bernard // Clinical Pharmacokinetics;2006, Vol. 45 Issue 1, p105 

    The article focuses on the views of the author on several ways which can be used for counterbalancing omitted doses. The authors suggest these ways should be referred to as hedging. In cases of delayed or omitted doses, which is known as partial compliance, substantially higher doses should be...

  • New PAH drug improves exercise capacity. Belden, Heidi // Drug Topics;7/23/2007, Vol. 151 Issue 14, p44 

    The article reports on the U.S. Food and Drug Administration's approval of once-daily oral tablet ambrisentan from Gilead Sciences Inc. for the treatment of pulmonary arterial hypertension with World Health Organization Functional Class II or III symptoms. The drug is an endothelin receptor...

  • Pulmonary Vascular Versus Right Ventricular Function Changes During Targeted Therapies of Pulmonary Hypertension. Vonk-Noordegraaf, Anton // Current Medical Literature: Pulmonary Hypertension;2012 Supplement, p20 

    The article focuses on a study which looks into the relationship between pulmonary vascular resistance (PVR) and right ventricular ejection fraction (RVEF) in patients with pulmonary hypertension (PH). The study has discovered changes in the right ventricular function and hypertensive pulmonary...

  • Current Management of Primary Pulmonary Hypertension. de Backer, T.L.M.; Smedema, J-P.; Carlier, S.G. // BioDrugs;2001, Vol. 15 Issue 12, p801 

    Primary pulmonary hypertension (PPH) is a rare disorder of the lung vasculature characterised by an increase in pulmonary artery pressure. Although the aetiology of this disease remains unknown, knowledge of the pathophysiology of the disease has advanced considerably. Diagnosis of PPH is...

  • Developing treatments for pulmonary arterial hypertension. Wilkins, Martin R. // Pulmonary Circulation;Jan-Mar2013, Vol. 3 Issue 1, p156 

    Developing new treatments for pulmonary arterial hypertension (PAH) is a challenge. We have enjoyed success with regulatory approvals for three drug classes-prostanoids, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. But we have also seen some disappointing results, for...

  • Effect of Sepimostat Mesilate on the Development of Glomerulonephritis in NZB/W F1 Mice. Watanabe, Hiroshi; Sato, Shuzo; Saito, Rie; Iwadate, Haruyo; Kobayashi, Hiroko; and Hiromasa Ohira // Open Immunology Journal;2011, Vol. 4, p11 

    Objective: To determine whether sepimostat mesilate inhibits activation of the complement pathways, and to evaluate the effectiveness of sepimostat mesilate on the development of glomerulonephritis in NZB/W F1 mice. Methods: We used the Wielisa complement functional kit to assess the inhibitory...

  • Somatuline Depot.  // Formulary;Oct2007, Vol. 42 Issue 10, p578 

    The article features Lanreotide drug from Ipsen Ltd. for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and radiotherapy, or for whom surgery and radiotherapy is not an option. Its effectivenes was evaluted in long-term, multiple-dose, randomized,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics